Sort
21,281 grants matching “influenza”
A VERSATILE NONINFECTIOUS PLATFORM FOR THE RAPID DEVELOPMENT AND UPDATING OF VACCINES AGAINST INFLUENZA A VIRUS OF SWINE
$649,943Board Of Regents Of The University Of Nebraska · · FY2025 · National Institute of Food and Agriculture
INFLUENZA A VIRUSES (IAV) CAUSE SIGINIFIANCT ECOMONIC LOSS IN LIVESTOCK INDUSTRY. THE ZOONOTIC NATURE OF THE VIRUS ALSO POSE A SIGNIFICANT PANDEMIC THREAT TO HUMAN POPULATION. PIGS HAVE LONG BEEN CONSIDERED A MIXING VESSEL FOR GENERATION OF NOVEL INFLUENZA VIRUSES. THE RECENT EMERGENCE AND OUTBREAKS OF HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) H5N1 VIRUS IN CATTLE HAVE INCREASED CONCERN OF IAV PANZOOTIC/PANDEMIC IN ANIMALS AND HUMAN POPULATION. AN UNIVERSAL VACCINE THAT CAN INDUCE STRONG, BROADLY PROTECTIVE IMMUNITY AGAINST GENETICALLY DIVERSIFIED VIRAL STRAINS IS URGENTLY NEEDED. CURRENT COMMERCIAL INFLUENZA VACCINE PLATFORMS AND MANUFACTURING PROCEDURES PRESENT A CHALLENGE FOR US TO RESPOND TO AN INFLUENZA OUTBREAK IN A TIMELY MANNER. NUCLEIC ACID-BASED (MRNA) VACCINE PLATFORMS ALLOW FOR FLEXIBLE, NIMBLE, LARGE-SCALE PRODUCTION OF VACCINES, WHICH CAN MEET THE RAPID MANUFACTURING REQUIREMENTS DURING AN INFLUENZA OUTBREAK. IN THIS PROPOSED STUDY, WE WILL TEST AN MRNA VACCINE COCKTAIL, WHICH CONTAINS A MIXTURE OF MRNAS ENCODING A CHIMERIC HA (H1) GLOBULAR HEAD, WITH TWO TYPES OF CONSERVED HA STALK DOMAIN COVERING 16 IAV SUBTYPES, AND THE H5 ANTIGEN FROM HPAI H5N1. THESE MRNAS WILL BE DELIVERED BY A NOVEL CLASS OF PEPTIDE-BASED CATIONIC NANOPARTICLES (PNP) FEATURING RESISTANCE TO OXIDATION AND THERMAL STABILITY. THIS CANDIDATE MRNA-PNP VACCINE WILL BE INITIALLY CHARACTERIZED IN CELL CULTURE MODEL AND THE IMMUNOGENICITY OF VACCINE WILL BE ASSESSED IN ANIMAL MODELS, INCLUDING PIGS AND CALVES.
$649,896University Of Illinois · · FY2025 · National Institute of Food and Agriculture
POULTRY INDUSTRY HAS BEEN SEVERELY IMPACTED SINCE 2014 BY THE OUTBREAKS OF THE HIGH PATHOGENIC AVIAN INFLUENZA (HPAI) VIRUSES, AND HUNDREDS OF MILLIONS OF CHICKENS AND TURKEYS HAVE BEEN SLAUGHTERED DUE TO THE HPAI OUTBREAKS IN THE UNITED STATES. SINCE 2021 A NOVEL TYPE OF HPAI H5N1 VIRUSES EMERGED IN NORTHAMERICA, ORIGINATED FROM EUROASIAN CONTINENTS, AND SPREAD TO HUNDREDS OF BOVINE CATTLE HERDS IN THE SPRING OF 2024, WHICH FURTHER DEVASTATED COMMERICAL AND BACKYARD POULTRY AS WELL AFTER FURTHER GENETIC MUTATIONS OCCURRED. FEW STUDIES HAVE BEEN CARRIED OUT TO UNDERSTAND HOW THE NEW HPAI H5N1 VIRUESES TRANSMIT AND CAUSE DISEASES IN POULTRY, AND NO VACCINES HAVE BEEN AVAILABLE TO STOP THESE OUTBREAKS. IN THIS PROPOSAL WE WILL COMARARTIVELY STUDY THREE H5N1 VIRUSES, THAT BELONG TO THE SAME 2.3.4.4B CLADE BUT FALL IN DIFFERENT EVOLUTIONARY STAGES, AND EXPLORE THEIR INFECTION, TRANSMISSION, AND THE DISEASE MECHANISMS IN CHICKENS AND TURKEYS. WE ALSO PROPOSE TO DEVELOP A NOVEL MICRORNA-BASED LIVE VACCINE TO CONTROL THE ONGOING OUTBREAKS OF THESE VIRUSES IN POULTRY. THE RESULT OF THIS STUDY WILL HELP US FURTHER UNDERSTAND THE NATURE OF THE NOVEL HPAI VIRUSES AND THE MECHANISMS OF THE INFECTIONS CAUSED BY THESE VIRUSES IN POULTRY. IT IS EXPECTED THAT MORE EFFECTIVE MEASURES AND POLICY RECOMMENDATIONS WILL ARISE FROM THIS STUDY FOR BETTER CONTROLLING THE SPREAD AND OUTBREAKS OF THE 2.3.4.4B CLADE HPAI IN POULTRY.
$649,815Regents Of The University Of Minnesota · · FY2025 · National Institute of Food and Agriculture
US Hospital Vaccine Effectiveness (VE) Network
$649,797Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2017 · IP
Flu vaccine effectiveness in those hospitalized in a large diverse health system
$649,797Richard K Zimmerman · University Of Pittsburgh At Pittsburgh · U01 · FY2017 · IP
Determining Influenza Vaccine Effectiveness (DIVE)
$649,796Helen Keipp Talbot · Vanderbilt University Medical Center · U01 · FY2017 · IP
Collaborative Research: DMREF: Predicting Molecular Interactions to Stabilize Viral Therapies
$649,767Sarah L Perry · University Of Massachusetts Amherst · · FY2021 · MPS
Targeting neutralizing epitopes in the MPER of HIV Env
$649,613Chinglai Yang · Emory University · R01 · FY2016 · AI
VACCINES FOR THE PREVENTION OF SWINE INFLUENZA PANDEMICS
$649,455Board Of Regents Of The University Of Nebraska · · FY2025 · National Institute of Food and Agriculture
Arsenic and immune response to influenza vaccination in pregnant women and newborns
$649,434Christopher D Heaney · Johns Hopkins University · R01 · FY2018 · ES
New Paradigms in Gene Regulation During Influenza Virus Infections
$649,247Curt M Horvath · Northwestern University · U01 · FY2013 · AI
Macrophage-targeting Nanoplatforms as Immunotherapy against Pulmonary Infections
$649,115Michael J Sailor · University Of California, San Diego · R01 · FY2025 · AI
Quantifying Error Growth to Improve Infectious Disease Forecast Accuracy
$649,085Jeffrey L Shaman · Columbia University Health Sciences · R01 · FY2023 · AI
Quantifying Error Growth to Improve Infectious Disease Forecast Accuracy
$649,085Jeffrey L Shaman · Columbia University Health Sciences · R01 · FY2022 · AI
Targeting RIPK3 in Age-Related Inflammation and Injury
$648,995Alexei Degterev · Tufts University Boston · R56 · FY2018 · AG
THE INFLUENZA VIRUS HAS BEEN RESPONSIBLE FOR SEVERAL PANDEMICS, AND HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) VIRUSES REMAIN A SIGNIFICANT THREAT TO PUBLIC HEALTH. A RECENT SPILLOVER OF THE HPAI H5N1 VIRUS TO DAIRY COWS HAS LED TO HUMAN INFECTIONS, HIGHLIGHTING THE NEED FOR SAFE AND EFFECTIVE VACCINES TO PREVENT INFLUENZA AIRWAY INFECTIONS IN COWS AND REDUCE SPREAD BETWEEN ANIMALS AND HUMANS. CURRENT INTRAMUSCULAR VACCINES, SUCH AS MRNA VACCINES, ARE HIGHLY EFFECTIVE IN REDUCING SEVERE DISEASES AND DEATHS BUT DO NOT PREVENT RESPIRATORY INFECTIONS AND TRANSMISSION. THIS LIMITATION ARISES BECAUSE INTRAMUSCULAR VACCINES PRIMARILY STIMULATE SYSTEMIC IMMUNITY, WHICH IS INSUFFICIENT FOR PROTECTING THE RESPIRATORY MUCOSA. TO ADDRESS THIS CHALLENGE, DEVELOPING MUCOSAL VACCINES THAT ELICIT LONG-LASTING MUCOSAL IMMUNITY IS ESSENTIAL. THESE VACCINES COULD PREVENT BOTH INITIAL AND RECURRENT INFLUENZA VIRUS INFECTIONS AND THEIR TRANSMISSION. RECENT STUDIES HAVE DEMONSTRATED THAT USING AN FCRN-BASED PLATFORM TO DELIVER INFLUENZA HEMAGGLUTININ (HA) AND SARS-COV-2 SPIKE ANTIGENS THROUGH THE AIRWAY CAN INDUCE PROTECTIVE MUCOSAL IMMUNITY IN BOTH THE NASAL AND LUNG COMPARTMENTS. THIS NASAL VACCINE EFFECTIVELY PREVENTS VIRUS REPLICATION IN ANIMALS AND LIMITS TRANSMISSION AMONG THEM. THESE FINDINGS LED US TO REASON THAT FCRN-MEDIATED NASAL SPRAY VACCINES FOR INFLUENZA CAN TRIGGER RECALL RESPONSES THAT PROTECT AGAINST INITIAL AND RECURRENT H5N1 INFECTIONS IN THE AIRWAY AND REDUCE ANIMAL-TO-ANIMAL AND ANIMAL-TO-HUMAN TRANSMISSION. GIVEN THE RAPIDLY EVOLVING NATURE OF INFLUENZA VIRUSES, WE AIM TO DEVELOP UNIVERSAL MUCOSAL VACCINES. THE VACCINES DELIVERED THROUGH THE FCRN PLATFORM CAN BE EASILY ENGINEERED, MANUFACTURED, AND ADAPTED FOR USE AGAINST OTHER MUCOSAL INFECTIONS IN LIVESTOCK.
$648,881University Of Maryland, College Park · · FY2025 · National Institute of Food and Agriculture
H. influenzae: Role of Sialic Acid in Virulence
$648,648Michael A. Apicella · University Of Iowa · R56 · FY2009 · AI
Ion channels regulating plasma cell differentiation and humoral immunity
$648,546Stefan Feske · New York University School Of Medicine · R01 · FY2025 · AI
Peripheral immune surveillance and long-lived barrier immunity through T cell DC cross-talk
$648,534Niroshana Anandasabapathy · Weill Medical Coll Of Cornell Univ · R56 · FY2021 · AR
Molecular pathogenesis of blastomycosis
$648,248Bruce Steven Klein · University Of Wisconsin-Madison · R37 · FY2022 · AI
Quantifying and modeling influenza viral dynamics and host responses
$648,075Paul Glyndwr Thomas · St. Jude Children'S Research Hospital · R56 · FY2011 · AI
Disease Modeling of Influenza and Other Emerging Respiratory Viral Pathogens
$648,038Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens
$647,499Marulasiddappa Suresh · University Of Wisconsin-Madison · U01 · FY2022 · AI
The Movement of Influenza Virus In Human Population
$646,933Katherine A Poehling · Wake Forest University Health Sciences · R01 · FY2013 · AI
Novel Influenza nano vaccines for broad cross protection
$646,873Baozhong Wang · Georgia State University · R01 · FY2023 · AI